Since January 1999, 16 pts in Italy were elegible to be treated according to ISG-SSG protocol for high risk Ewing's sarcoma (pts with multiple lung or pleural metastases and/or solitary bone metastases, age Ͻ40 yrs). They are 10 males and 6 females, 7 Ͻ15 yrs old and 9 Ͼ15 yrs old. Site of disease were: 4 femur, 5 pelvis, 3 ribs, 1 tibia, 1 vertebra, 1 scapula, 1 fibula. Metastases were in the lung in all pts but in two, who had pleural effusion with Askin tumour, LDH at diagnosis was high in 8 cases and 4 pts had fever at presentation. Treatment consists of 4 cycles of induction chemotherapy (alternating VAI to CTX 4 gr/sqm/VP16 600 mg/sqm) supported by G-CSF, with PBSC collection after the second cycle, followed by local treatment; further four cycles of VAC alternated to VP16/IFO, and finally, in responding pts, high dose chemotherapy with Busulfan 16 mg/kg, Alkeran 140 mg/sqm plus PBSC, following by total lung irradiation. Median amount of harvested CD 34+ cells was 9.5 milion/kg (6.7-36). After induction chemotherapy CR or PR of lung metastases and primary tumour was achieved in 11 out of 13 evaluable pts. Four pts underwent surgery of bone tumour, while 7 pts received radiotherapy (2 pts palliative radiotherapy in progressive disease). Regarding toxicity in 8 pts who received high dose chemotherapy, they had 3 days with fever Ͼ 38°, median time to granulocytes and platelets recovery was respectively 6 and 4 days, severe stomatitis in 2 pts for 3 days, without any major toxicity. So far only 6 pts received all the planned treatment, 4 are NED at 11, 11, 14, 15 months, 2 AWD both at 22 months. The ISG-SSG protocol is feasible as it regards the drug doese and the schedule. Further follow up is necessary to draw conclusions about efficacy and late toxicity.
WP140
The role of High-Dose Chemotherapy (HDCT) in patients with relapsed pure seminoma O. Rick, W. Siegert, N. Schwella, M. Dubiel, A. Krusch, J. Beyer (Berlin, Marburg, D) Purpose: We assessed response and long-term survival after HDCT in patients with relapsed seminoma. Patients and Methods: Between October 1989 and February 1997, 196 patients with relapsed and/or refractory germ cell tumors (GCT) were treated with HDCT as part of consecutive phase I/II studies. Among this group were 13 patients with histologically confirmed pure seminomas. All 13 patients had failed prior cisplatin-based first-line with or without subsequent salvage chemotherapy. Each phase I/II study consisted of one or more cycles of conventional-dose chemotherapy followed by one cycle of HDCT. Results: One patient developed multiorgan failure after HDCT and died. Among the remaining patients 4/12 (33%) became disease-free, 4/12 patients (33%) achieved a partial remission and 4/12 patients (33%) suffered progressive disease despite HDCT. With a median follow-up of 4.5 years (range 3.4 to 8 years) 5/13 patients (38%) are alive and 8/13 patients (62%) have died. Patients with poor responses to prior treatments and those with short relapse-free intervals were more likely to fail HDCT. Conclusions: HDCT can have curative potential in patients with multiply relapsed pure seminoma patients. However, patients with inadequate responses to previous chemotherapy or short relapse-free intervals have poor outcomes. Phase II studies report encouraging response rates after HDC with peripheral blood stem cells (PBSC) support in AOC, but response duration is usually short. Here, we report the preliminary results of a phase II trial in AOC with a new front line sequential HDC regimen. Patients (pts) were treated with 3 cycles of ED (Epirubicin 125 mg/sqm and Docetaxel 75 mg/sqm iv q3 wks) plus Filgrastim (Amgen/Roche) 5 mcg/kg/d as induction chemotherapy. Leukaphereses were performed after 7-12 days after chemotherapy and a minimum of 6 x 10e6 CD34+ cells/kg collected. Induction therapy was followed by 3 cycles of HD-ICE (IFO: 2.5 g/sqm/d, CBDCA: AUC 4/d and VP16: 300 mg/sqm/d for 4 days) at monthly intervals, with PBSC reinfusion and Filgrastim 5 mcg/kg/d support until recovery. 16 pts were treated, 13 of whom are fully evaluable: 12 pts completed treatment, while 1 pt was withdrawn due to persistent G4 neutropenia. All pts had unfavorable tumor presentation with elevated tumor burden at diagnosis (11 pts) or Ͼ=2 cm residual tumor after surgery (2 pts). 10 pts collected the requested amount of CD34 + cells in a single apheresis. The mean number of CD34+ cells/kg collected was 11.7 x10e6 with a range of 6-27.5. The mean number of CD34+ cells/kg reinfused after the 3 HD-ICE courses was 4.18 (range 2-9.16). A total of 39 ED cycles and 38 HD-ICE cycles were administered. ED was well tolerated: G3-4 neutropenia without fever occurred in 5 pts. Main toxicities for HD-ICE were G4 neutropenia in 12 pts, G4 thrombocytopenia in 13 pts (mean PLT transfusions: 4.23, range 1-9), G3 anemia in 10 pts (mean RBC transfusions: 2.3, range 1-8). Only mild neurotoxicity was observed, while G2 reversible renal toxicity occurred in 1 pt. The mean number of days with WBCϽ1000 and PLTϽ10000 was 6.6 and 1.5, respectively. After ED, 2 pts achieved clinical complete remission (CR) and 10 pts achieved clinical partial remission (PR). After HD-ICE, second look laparoscopy or laparotomy was performed in 4 and 8 pts, with pCR and PR in 5 pts and 7 pts, respectively (overall RR 100 %). After a median follow-up of 11 months, 67% (8/12) of pts are alive: 5 disease free, 3 with disease. For pts who achieved CR, DFS is 100% at a median follow-up of 19.5 months (range 6.5-32). These preliminary data suggest that sequential HDC with repeated transplant is feasible and safe; ED is effective and mobilizes optimally CD34+ cells. Overall RR and DFS are encouraging. Phase III trials are ongoing.
